Eli Lilly paid $100 million upfront for rights to CSL’s phase 3 IL-6 antibody, previously tested for organ transplant rejection after a failed phase 3 study.
Longevity News
Eli Lilly is paying $100 million upfront for the right to develop CSL’s phase 3-stage IL-6 antibody that had previous...
Source: FierceBiotech - All • Published: 18 Feb 2026, 10:55
Continue exploring
Related longevity signals
TechCrunchMichael Polansky is training an AI model on skin that’s still aliveReport on a startup combining living human skin tissue maintenance with AI to accelerate discovery of new topical cosmetic compounds and testing workflows.Lifespan.ioA Million-Person Study Finds a Protective Metabolic GeneHuman genetics research exploring metabolic regulation and disease risk, previewing an article that examines gene-based discoveries and potential therapeutic pathways.Nature - BiotechnologyOral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trialReports a multicenter phase II trial testing an oral nonpeptide GLP-1 receptor agonist for obesity, its dosing options, and short-term efficacy and tolerability.PR NewswireAureka Biotechnologies Raises US$100 Million Series B to Build a Biological World Model for Drug DiscoveryA biotech funding story about a startup scaling AI-native drug discovery and building biological foundation models; a look at its R&D strategy and platform.